⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19126 | 1.00 | — | — | |
| SCHEMBL19125 | 1.00 | — | — | |
| SCHEMBL16513220 | 1.00 | — | — | |
| SCHEMBL16513221 | 1.00 | — | — | |
| SCHEMBL3558663 | 0.72 | — | — | |
| SCHEMBL20395709 | 0.72 | — | — | |
| SCHEMBL3558664 | 0.72 | — | — | |
| SCHEMBL4392555 | 0.70 | — | — | |
| SCHEMBL4401210 | 0.70 | — | — | |
| SCHEMBL80093 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113348165-B | 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | 拜耳股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114514223-B | Process for enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines comprising using novel iridium catalysts | 拜耳公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| US-11878027-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| CN-111902399-B | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-116925070-A | Substituted aza-fused ring compounds and medical uses thereof | 扬子江药业集团有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1861378-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007079982-A1 | (2 , 4 , 9-TRIAZA-1 (2 , 4 ) -PYRIMIDINA-3 ( 1 , 3 ) -BENZENACYCLONONAPHANE-3 4-YL) -SULFOXIMINE DERIVATIVES AS SELECTIVE AURORA KINASE INHIBITORS FOR THE TREATMENT OF CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1803723-A1 | (2,4,9-TRIAZA-1(2,4)-PYRIMIDINA-3(1,3)-BENZENACYCLONONAPHAN-3^4-YL)-SULFOXIMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF THE AURORA KINASE FOR THE TREATMENT OF CANCER | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006099974-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |